Overview of Dr. Funt
Dr. Samuel Funt is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Memorial Hospital for Cancer and allied Diseases, Memorial Hospital for Cancer and allied Diseases, and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Emory University School of Medicine and has been in practice 7 years. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 89 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He also speaks multiple languages, including Spanish. He has more than 60 publications and over 500 citings.
Office
353 East 68th Street
New York, NY 10065
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2016
New York Presbyterian Hospital (Columbia Campus)Chief Residency, Internal Medicine, 2013 - 2014- New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2010 - 2013
Emory University School of MedicineClass of 2010
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2011 - 2026
CT State Medical License 2023 - 2025
NJ State Medical License 2019 - 2025
PA State Medical License 2022 - 2024
NC State Medical License 2021 - 2022- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2013-2016
Clinical Trials
- A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer Start of enrollment: 2016 Dec 20
- Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Start of enrollment: 2017 May 15
- Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract Start of enrollment: 2018 Jan 31
Publications & Presentations
PubMed
- Long-term Clinical Outcomes of Patients With Negative Pathology (pN0) at Primary Retroperitoneal Lymph Node Dissection.Fady Baky, Nicole Liso, Brandon Williams, Andrea Knezevic, Samuel A Funt
Clinical Genitourinary Cancer. 2024-12-01 - 1 citationsLong-term Outcomes of Regressed or "Burnt Out" Primary Testicular Germ Cell Tumors.Fady J Baky, Nicole Liso, Brandon Williams, Victor E Reuter, Satish K Tickoo
Urology. 2024-11-01 - Perioperative Serum MicroRNA 371a-3p and 372-3p Levels in Patients with Clinically Localized Testicular Masses.Richard S Matulewicz, Fady Baky, Andrea Knezevic, Joel Sheinfeld, Brandon M Williams
European Urology Open Science. 2024-10-01
Lectures
- A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC).2019 ASCO Annual Meeting - 6/1/2019
- Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Neoadjuvant Atezolizumab–Chemotherapy ‘Worthy of Investigation’ for MIBCFebruary 14th, 2022- A Pipeline to a Medical CareerAugust 19th, 2021
- Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. FuntJuly 29th, 2021
- Join now to see all
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
